% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Park:299549,
      author       = {S.-Y. Park and E. Pylaeva$^*$ and V. Bhuria and A. R.
                      Gambardella and G. Schiavoni and D. Mougiakakos and S.-H.
                      Kim and J. Jablonska$^*$},
      title        = {{H}arnessing myeloid cells in cancer.},
      journal      = {Molecular cancer},
      volume       = {24},
      number       = {1},
      issn         = {1476-4598},
      address      = {London},
      publisher    = {Biomed Central},
      reportid     = {DKFZ-2025-00493},
      pages        = {69},
      year         = {2025},
      abstract     = {Cancer-associated myeloid cells due to their plasticity
                      play dual roles in both promoting and inhibiting tumor
                      progression. Myeloid cells with immunosuppressive properties
                      play a critical role in anti-cancer immune regulation. Cells
                      of different origin, such as tumor associated macrophages
                      (TAMs), tumor associated neutrophils (TANs), myeloid derived
                      suppressor cells (also called MDSCs) and eosinophils are
                      often expanded in cancer patients and significantly
                      influence their survival, but also the outcome of
                      anti-cancer therapies. For this reason, the variety of
                      preclinical and clinical studies to modulate the activity of
                      these cells have been conducted, however without successful
                      outcome to date. In this review, pro-tumor activity of
                      myeloid cells, myeloid cell-specific therapeutic targets, in
                      vivo studies on myeloid cell re-polarization and the impact
                      of myeloid cells on immunotherapies/genetic engineering are
                      addressed. This paper also summarizes ongoing clinical
                      trials and the concept of chimeric antigen receptor
                      macrophage (CAR-M) therapies, and suggests future research
                      perspectives, offering new opportunities in the development
                      of novel clinical treatment strategies.},
      subtyp        = {Review Article},
      keywords     = {Humans / Neoplasms: immunology / Neoplasms: therapy /
                      Neoplasms: pathology / Animals / Myeloid Cells: immunology /
                      Myeloid Cells: metabolism / Immunotherapy: methods / Tumor
                      Microenvironment: immunology / Myeloid-Derived Suppressor
                      Cells: immunology / Myeloid-Derived Suppressor Cells:
                      metabolism / Eosinophils (Other) / Immunosuppression (Other)
                      / Macrophages (Other) / Myeloid cells (Other) / Neutrophils
                      (Other) / Therapeutic target (Other)},
      cin          = {ED01},
      ddc          = {570},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40050933},
      doi          = {10.1186/s12943-025-02249-2},
      url          = {https://inrepo02.dkfz.de/record/299549},
}